Home
Anumana

Anumana Market Share Analysis for August 2026

"Anumana is a leading AI-driven health technology company leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never before. The company was founded by nference in collaboration with... More

Industry: N/A

Domainanumana.ai

Year Founded2021

Employees51 - 200

Annual Revenue--

Anumana

Anumana (including company regionals)

anumana.ai

See more website traffic and engagement information

Total visits to Anumana's top domains

Understand Anumana market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

anumana.ai5.5K

See more with Sales Intelligence

Avg. visit duration in Anumana's top domains

Analyze Anumana engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

anumana.ai00:00:40

See more with Sales Intelligence

Avg. pageviews on Anumana's top domains

See how Anumana keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

anumana.ai2.05

See more with Sales Intelligence

Anumana top competitors by domain

Top similar sites in August 2026, ranked by their affinity

nference.comCompany NamenferenceEmployees201 - 500HQUnited States, Massachusetts, CambridgeAnnual revenue--Total visits8KHealth > Health - Other

Top technologies used by Anumana

These are the website technologies, by industry, used by Anumana top domains

Payment & Currencies (8)

Cart Functionality

Advertising (4)

DoubleClick

Content Management System (3)

WordPress

Conversion & Analytics (3)

Google Analytics

More Technologies

11

See all

News & Signals from Anumana

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAnumana Inc. launched AI-driven software-as-a-medical-device on Apr 8th '26.Cardiac amyloidosis is a serious, life-threatening condition caused by abnormal protein deposits in the heart that can lead to heart failure if not recognized early.[1] It is frequently underdiagnosed due to nonspecific symptoms that overlap with common cardiac conditions.[2] Early diagnosis is critical, and timely intervention can meaningfully improve outcomes for patients.[3] While a standard ECG is routinely obtained during the evaluation of these symptoms, human interpretation often misses the subtle combinations of features that may indicate CA.[4] With FDA clearance, Anumana's AI-driven software-as-a-medical-device (SaMD) is now available for clinical use, enabling analysis of ECG data to help identify patients who may benefit from further evaluation.

NewsAnumana Inc. partnered with AliveCor, Inc. on Jan 1st '25.In January 2025, Anumana partnered with AliveCor for the development of its AI algorithms intended for the early identification of cardiac diseases.

NewsAnumana Inc. recognized as 2026 Most Innovative Companies list in the Medical Devices category on Mar 24th '26.CAMBRIDGE, Mass., March 24, 2026 - Anumana, a leader in AI-powered cardiovascular detection algorithms, today announced it has been named to Fast Company's prestigious 2026 Most Innovative Companies list in the Medical Devices category.